Table 1.
Baseline and clinical characteristics of the female patients with COVID-19.
| Female COVID-19 patients | ||
|---|---|---|
| Characteristic | ||
| Age, years | ||
| Median (IQR) | 43.50 (36.75–47.00) | |
| Distribution, n/N (%) | ||
| 10–30 | 5/78 (6.41) | |
| 31–40 | 23/78 (29.49) | |
| 41–50 | 50/78 (64.10) | |
| Severe group, n/N (%) | 17/78 (21.79) | |
| Body mass index (BMI), median (IQR) | 22.7 (20.15–25.18) | |
| Recent mental disorder, n/N (%) | 36/75 (48.00) | |
| Exposure history, n/N (%) | 68/78 (87.20) | |
| Residents of Wuhan, n/N (%) | 71/78 (91.03) | |
| Menarche, median (IQR) | 13 (12–13) | |
| Reproductive history, n/N (%) | ||
| Gravidity | 2 (2–3) | |
| Parity | 1 (1–1.5) | |
| Abortion times | 1 (0–2) | |
| Medical history, n/N (%) | ||
| Comorbidities | 17/78 (21.79) | |
| Benign gynecological disease | 9/75 (12.00) | |
| Gynecological surgery history | 27/75 (36.00) | |
| Symptoms on admission, n/N (%) | ||
| Fever | 58/78 (74.36) | |
| Cough | 28/78 (35.90) | |
| Sore throat | 0/78 (0) | |
| Fatigue | 4/78 (5.13) | |
| Myalgia | 1/78 (1.28) | |
| Dyspnea | 8/78 (10.26) | |
| Diarrhea | 4/78 (5.13) | |
| Therapy, n/N (%) | ||
| Antiviral treatment | 45/74 (60.81) | |
| Antibiotic treatment | 44/74 (59.46) | |
Median (IQR): continuous variables were expressed as medians and interquartile ranges (IQR) as appropriate; n/N (%): categorical variables were summarized as the counts and percentages (%) in each category.